PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Mesoblast

Status and phase

Completed

Phase 2

Conditions

Chronic Bronchitis

Pulmonary Emphysema

Pulmonary Disease, Chronic Obstructive

Treatments

Drug: Prochymal™

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00683722

801

Details and patient eligibility

About

The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

Full description

COPD is currently the fourth leading cause of death in the United States. It is clear that there is a significant unmet medical need for safe and effective therapies to treat moderate to severe COPD. This patient population has a high mortality rate and requires frequent hospitalizations due to disease-related exacerbations. Based on severity distribution estimates, approximately 70% of all current COPD patient have either moderate or severe COPD. COPD has no known cure, thus current therapeutic intervention is aimed at providing relief of symptoms. Oxygen therapy is the only treatment that has been shown to improve survival. Smoking cessation has been shown to slow the rate of forced expiratory volume in 1 second (FEV1) decline and COPD progression. In general patient are treated with bronchodilators and inhaled corticosteroids, but again, these measures do not provide any significant benefit regarding disease progression or prognosis. The characteristics and biologic activity of Prochymal™, along with a good safety profile in human trials to date, suggest that Prochymal™ may be a good candidate for addressing this unmet medical need.

Enrollment

62 patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participant must have a diagnosis of moderate or severe COPD.
Participant must have a post-bronchodilator FEV1/forced vital capacity (FVC) ratio < 0.7.
Participant must have a post-bronchodilator FEV1 % predicted value ≥ 30% and < 70%.
Participant must be between 40 and 80 years of age, of either sex, and of any race.
Participant must be a current or ex-smoker, with a cigarette smoking history of ≥ 10 years or > 10 pack-years.

Exclusion criteria

Participant has been diagnosed with asthma or other clinically relevant lung disease other than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, or lung cancer).
Participant has been diagnosed with α1-antitrypsin deficiency.
Participant has a body mass greater than 150 kg (330 lb) or less than 40 kg (88 lb).
Participant has active infection.
Participant has had a significant exacerbation of COPD or has required mechanical ventilation within 4 weeks of screening.
The participant with clinically relevant uncontrolled medical condition not associated with COPD.
Participant has documented history of uncontrolled heart failure.
Participant has pulmonary hypertension due to left heart condition.
Participant has atrial fibrillation or significant congenital heart defect/disease.
Participant has initiated pulmonary rehabilitation within 3 months of screening.
Participant is allergic to bovine or porcine products.
Participant has evidence of active malignancy, or prior history of active malignancy that has not been in remission for at least 5 years.
Participant has a life expectancy of < 6 months.